Matthew M. Hsieh

Matthew M. Hsieh

Auto-generated profile, based on publicly available information

Matthew M. Hsieh

Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
JMJean-Yves Métais
Jean-Yves Métais
PDPhillip A. Doerfler
Phillip A. Doerfler
TMThiyagaraj Mayuranathan
Thiyagaraj Mayuranathan
DBDaniel E. Bauer
Daniel E. Bauer
SFStephanie C. Fowler
Stephanie C. Fowler
MWMitchell J. Weiss
Mitchell J. Weiss
Key Points: Cas9 editing of the γ-globin gene promoters in hematopoietic stem cells (HSCs) increases red cell HbF by ≤40%. No deleterious effects on hematopoiesis or off-target mutations were detected 16 weeks after xenotransplantation of edited HSCs.

26 October 2017 in Blood
Verified
Journal Article
Closed access
PDF file
CFCourtney Fitzhugh
Courtney Fitzhugh
SCStefan Cordes
Stefan Cordes
TTTiffani Taylor
Tiffani Taylor
WCWynona Coles
Wynona Coles
KRKatherine Roskom
Katherine Roskom
JTJohn F. Tisdale
John F. Tisdale
Key Points: Results based on our allogeneic model suggest genetic strategies aimed at correcting at least 20% of HSCs are necessary to reverse SCD. A minority of donor myeloid cells is adequate because of the vast differences in RBC survival between donor and recipient.

12 May 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
MHMatthew M. Hsieh
Matthew M. Hsieh
MBMelissa Bonner
Melissa Bonner
FPFrancis John Pierciey
Francis John Pierciey
NUNaoya Uchida
Naoya Uchida
JRJames Rottman
James Rottman
JTJohn F. Tisdale
John F. Tisdale
Key Points: Ability to accurately attribute adverse events post–gene therapy is required to describe the benefit-risk of these novel treatments. A SCD patient developed myelodysplastic syndrome post-LentiGlobin treatment; we show how insertional oncogenesis was excluded as the cause.

7 September 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
RMRobert Molokie
Robert Molokie
DLDonald Lavelle
Donald Lavelle
MGMichel Gowhari
Michel Gowhari
MPMichael Pacini
Michael Pacini
LKLani Krauz
Lani Krauz
YSYogen Saunthararajah
Yogen Saunthararajah
Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible global morbidity and mortality, is driven by polymerization of mutated sickle hemoglobin (HbS) in red blood cells (RBCs). Fetal hemoglobin (HbF) interferes with this polymerization, but HbF is epigenetically silenced from infancy onward by DNA methyltransferase 1 (DNMT1). To pharmacologically re-induce HbF by DNMT1 inhibition, this first-in-human clinical trial (NCT01685515) combined 2 small molecules—decitabine to deplete DNMT1 and tetrahydrouridine (THU) to inhibit cytidine deaminase (CDA), the enzyme that otherwise rapidly deaminates/inactivates decitabine, severely limiting its half-life, tissue distribution, and oral bioavailability. Oral decitabine doses, administered after oral THU 10 mg/kg, were escalated from a very low starting level (0.01, 0.02, 0.04, 0.08, or 0.16 mg/kg) to identify minimal doses active in depleting DNMT1 without cytotoxicity. Patients were SCD adults at risk of early death despite standard-of-care, randomized 3:2 to THU–decitabine versus placebo in 5 cohorts of 5 patients treated 2X/week for 8 weeks, with 4 weeks of follow-up. The primary endpoint was ≥ grade 3 non-hematologic toxicity. This endpoint was not triggered, and adverse events (AEs) were not significantly different in THU-decitabine—versus placebo-treated patients. At the decitabine 0.16 mg/kg dose, plasma concentrations peaked at approximately 50 nM (Cmax) and remained elevated for several hours. This dose decreased DNMT1 protein in peripheral blood mononuclear cells by >75% and repetitive element CpG methylation by approximately 10%, and increased HbF by 4%–9% (P < 0.001), doubling fetal hemoglobin-enriched red blood cells (F-cells) up to approximately 80% of total RBCs. Total hemoglobin increased by 1.2–1.9 g/dL (P = 0.01) as reticulocytes simultaneously decreased; that is, better quality and efficiency of HbF-enriched erythropoiesis elevated hemoglobin using fewer reticulocytes. Also indicating better RBC quality, biomarkers of hemolysis, thrombophilia, and inflammation (LDH, bilirubin, D-dimer, C-reactive protein [CRP]) improved. As expected with non-cytotoxic DNMT1-depletion, platelets increased and neutrophils concurrently decreased, but not to an extent requiring treatment holds. As an early phase study, limitations include small patient numbers at each dose level and narrow capacity to evaluate clinical benefits. Administration of oral THU-decitabine to patients with SCD was safe in this study and, by targeting DNMT1, upregulated HbF in RBCs. Further studies should investigate clinical benefits and potential harms not identified to date. ClinicalTrials.gov, NCT01685515

19 April 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
CFCourtney Fitzhugh
Courtney Fitzhugh
MHMatthew M. Hsieh
Matthew M. Hsieh
TTTiffani Taylor
Tiffani Taylor
WCWynona Coles
Wynona Coles
KRKatherine Roskom
Katherine Roskom
JTJohn F. Tisdale
John F. Tisdale
Key Points: Patients with SCD and severe organ damage can tolerate nonmyeloablative conditioning with no transplant-related mortality. Posttransplant cyclophosphamide prevents severe GVHD, increases engraftment, and improves the success rate for haploidentical HSCT.

3 February 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MAMohsen Alzahrani
Mohsen Alzahrani
MDMoussab Damlaj
Moussab Damlaj
NJNeal Jeffries
Neal Jeffries
BABader Alahmari
Bader Alahmari
ASAvani Singh
Avani Singh
MHMatthew M. Hsieh
Matthew M. Hsieh